Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Tamura

Showing results (1-10 of 379) with videos related to

Pageof 38
Sort By:
Japanese Journal of Clinical Oncology|October 31, 2019
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancerKenji Tamura
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Molecular target therapy]Kenji Tamura
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 24, 2010
[Development of new molecular target drug]Kenji Tamura
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|February 17, 2009
[EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers]Kenji Tamura
Japanese Journal of Clinical Oncology|October 22, 2015
Development of cell-cycle checkpoint therapy for solid tumorsKenji Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 20, 2008
[Targeted therapies for lung cancer]Kenji Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 13, 2012
[DNA repair pathway and molecularly targeted therapy for malignant tumors]Kenji Tamura
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2010
[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]Kenji Hashimoto, Kenji Tamura
International Journal of Clinical Oncology|September 5, 2003
Molecular target-based cancer therapy: tyrosine kinase inhibitorsKenji Tamura, Masahiro Fukuoka
Chemsuschem|June 27, 2026
Cosolvent-Enhanced Dissolution of Long-Chain Polyamides: Toward Room-Temperature Material Recycling of Sustainable CompositesJonathon Tanks, Kenji Tamura
Pageof 38

Showing results (1-10 of 379) with videos related to

Sort By:
Pageof 38
Japanese Journal of Clinical Oncology|October 31, 2019
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancerKenji Tamura
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Molecular target therapy]Kenji Tamura
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 24, 2010
[Development of new molecular target drug]Kenji Tamura
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|February 17, 2009
[EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers]Kenji Tamura
Japanese Journal of Clinical Oncology|October 22, 2015
Development of cell-cycle checkpoint therapy for solid tumorsKenji Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 20, 2008
[Targeted therapies for lung cancer]Kenji Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 13, 2012
[DNA repair pathway and molecularly targeted therapy for malignant tumors]Kenji Tamura
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2010
[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]Kenji Hashimoto, Kenji Tamura
International Journal of Clinical Oncology|September 5, 2003
Molecular target-based cancer therapy: tyrosine kinase inhibitorsKenji Tamura, Masahiro Fukuoka
Chemsuschem|June 27, 2026
Cosolvent-Enhanced Dissolution of Long-Chain Polyamides: Toward Room-Temperature Material Recycling of Sustainable CompositesJonathon Tanks, Kenji Tamura
Pageof 38